All In Biotech

Free tool

FAERS Monitor: Impavido

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204684 or its brand name (Impavido, Miltefosine). Reports on generic versions are filed under their own applications.

Reports

388

Serious

377

97% of reports

Hospitalization

133

Death reported

121

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use122
  • drug ineffective109
  • nausea59
  • drug ineffective for unapproved indication57
  • condition aggravated33
  • vomiting33
  • product use in unapproved indication26
  • disease recurrence24
  • decreased appetite22
  • visceral leishmaniasis20
  • renal failure18
  • acute kidney injury17
  • toxicity to various agents16
  • acanthamoeba infection15
  • gastrointestinal disorder15

Reports by year received

View as table
YearReports
20041
20061
20071
20092
20101
20115
20134
201416
201511
20168
201723
201829
201931
202032
202146
202227
202331
202432
202558
202629

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,771 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acanthamoeba infectionSignal154704.82802.560,658
visceral leishmaniasisSignal201545.91002.428,541
drug ineffective for unapproved indicationSignal5756.444.33,049
disease recurrenceSignal2427.418.6584
gastrointestinal disorderSignal159.15.5100
off label useSignal1227.66.5717
renal failureSignal187.34.793
acute kidney injurySignal176.03.867
condition aggravatedSignal335.94.2131
product use in unapproved indicationSignal265.73.997
toxicity to various agentsSignal165.13.250
decreased appetiteSignal225.13.470
drug ineffectiveSignal1094.53.8311
nauseaSignal594.03.2137
vomitingSignal333.82.767

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.